Appetite stimulants

PURA Acquires KALY CBD Confections Hemp4mula Business

Retrieved on: 
Friday, March 13, 2020
Entheogens, Euphoriants, Appetite stimulants, KALY, Cannabis, CBD, Central Business District, Singapore, Medicine, Medical specialties, Plants

DALLAS, March 13, 2020 /PRNewswire/ -- Puration, Inc. (USOTC: PURA) and Kali-Extracts (USOTC: KALY) announced today that PURA has acquired KALY's Hemp4mula CBD Confections business.

Key Points: 
  • DALLAS, March 13, 2020 /PRNewswire/ -- Puration, Inc. (USOTC: PURA) and Kali-Extracts (USOTC: KALY) announced today that PURA has acquired KALY's Hemp4mula CBD Confections business.
  • The Hemp4mula CBD Confections line today sells CBD infused gummies and gum.
  • KALY is selling the operation to streamline its focus on its ongoing cannabis biopharmaceutical business.
  • As detailed in a recently publishedresearchstudy ( Journal of Cannabis Research ) the KALY U.S. Patented CBD extract provides significant anti-inflammatory responsesin vitro.

Maryland University of Integrative Health announces new program in Cannabis Science: Therapeutics, Product Design, and Quality Assurance

Retrieved on: 
Monday, March 9, 2020
Appetite stimulants, Entheogens, Euphoriants, Medicine, Laurel, Maryland, Maryland University of Integrative Health, Cannabis, Quality assurance, Alternative medicine, Medical specialties

LAUREL, Md., March 9, 2020 /PRNewswire/ -- Maryland University of Integrative Health (MUIH) announced today that it has submitted a new program proposal to the Maryland Higher Education Commission (MHEC) for approval the Post-Baccalaureate Certificate in Cannabis Science: Therapeutics, Product Design, and Quality Assurance .

Key Points: 
  • LAUREL, Md., March 9, 2020 /PRNewswire/ -- Maryland University of Integrative Health (MUIH) announced today that it has submitted a new program proposal to the Maryland Higher Education Commission (MHEC) for approval the Post-Baccalaureate Certificate in Cannabis Science: Therapeutics, Product Design, and Quality Assurance .
  • The program examines the science behind cannabis and investigates the evidence for therapeutic benefits and risks, issues in product design and quality assurance.
  • The program educates students about cannabis-based products with an emphasis on health effects, safety, formulation, and quality assurance.
  • Deeply rooted in a holistic philosophy, its model for integrative health and wellness is grounded in whole-person, relationship-centered, evidence-informed care.

Khiron Poised to Enter Medical Cannabis Market in Peru

Retrieved on: 
Thursday, March 5, 2020
Entheogens, Euphoriants, Medicinal plants, Medicine, Drugs, Appetite stimulants, Herbalism, Health, Cannabis, Tetrahydrocannabinol, Legality of cannabis, Medical cannabis

of Per, a leading pharmacy chain and manufacturing laboratory based in Lima, to manufacture and distribute Khiron-branded medical cannabis magistral preparations in Per.

Key Points: 
  • of Per, a leading pharmacy chain and manufacturing laboratory based in Lima, to manufacture and distribute Khiron-branded medical cannabis magistral preparations in Per.
  • In Peru, only registered pharmaceutical establishments who have fulfilled GSP requirements are authorized to participate in wholesale import and commercialization of cannabis products.
  • The Company expects to begin sales in Peru once it obtains its import license from DIGEMID and Farmacia Universal S.A.C.
  • "Khiron is currently the only Colombian Company with high-THC quotas for export purposes, including into Peru, and considers the country one of the key medical cannabis markets in Latam.

Charlotte's Web 2019 Harvest Delivers 10% Increase in Yield and 22% Increase in CBD Potency due to Proprietary Genetics

Retrieved on: 
Wednesday, March 4, 2020
Drugs, Organ systems, Anticonvulsants, Entheogens, Euphoriants, Appetite stimulants, Cannabidiol, Cannabinoids, Tetrahydrocannabinol, Charlotte's Web

The results of the 2019 harvest versus the 2018 are as follows:

Key Points: 
  • The results of the 2019 harvest versus the 2018 are as follows:
    245% increase in total dried biomass to 2.34million lbs.
  • "We are very pleased with the results of the 2019 harvest, achieving yield and potency levels that surpassed our expectations.
  • Developed by Charlotte's Web Senior Director of Cultivation Research & Development, Bear Reel, both exceeded expectations for CBD potency, low THC, and superior yield.
  • Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD capsules, CBD topicals, as well as CBD pet products.

qemp Launches Whole Spectrum, Hemp-Derived CBD Product Line Powered By Nature's Sunshine

Retrieved on: 
Tuesday, March 3, 2020
Drugs, Organ systems, Appetite stimulants, Entheogens, Euphoriants, Psychoactive drugs, Anticonvulsants, Cannabidiol, Cannabinoids, Hemp, Cannabis, Tetrahydrocannabinol

"We're excited to enter the CBD market with a unique line of products that draw upon Nature's Sunshine's unparalleled knowledge and scientific expertise in the herbal and natural supplement industry," said Eddie Silcock, President of qemp.

Key Points: 
  • "We're excited to enter the CBD market with a unique line of products that draw upon Nature's Sunshine's unparalleled knowledge and scientific expertise in the herbal and natural supplement industry," said Eddie Silcock, President of qemp.
  • This hybrid approach results in a targeted and effective CBD product line that naturally helps activate and balance the body's endocannabinoid system.
  • All qemp CBD products are made from quality, whole spectrum hemp extract to provide a full profile of phytocannabinoids and contain 0.3% THC or less.
  • About qemp:Backed by Nature's Sunshine Products, qemp is THE premium quality, hemp-derived CBD oil on the market.

PURA and KALY Confirm CBD Confections Acquisition Plans as KALY Gains Potential Coronavirus Treatment Momentum

Retrieved on: 
Monday, March 2, 2020
Medicine, Health, Branches of biology, Appetite stimulants, Entheogens, Euphoriants, Herbalism, Medicinal plants, KALY, Cannabis, Tetrahydrocannabinol, Respiratory disease

DALLAS, March 2, 2020 /PRNewswire/ -- Puration, Inc. (USOTC: PURA) and Kali-Extracts (USOTC: KALY) today confirmed the planned acquisition by PURA of KALY's CBD Confections Operations is proceeding.

Key Points: 
  • DALLAS, March 2, 2020 /PRNewswire/ -- Puration, Inc. (USOTC: PURA) and Kali-Extracts (USOTC: KALY) today confirmed the planned acquisition by PURA of KALY's CBD Confections Operations is proceeding.
  • KALY confirmed efforts earlier today to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms.
  • KALY's proprietaryCBD formulation has been developed for the treatment of symptoms associated withChronic Obstructive Pulmonary Disease (COPD)and other similar respiratory conditions.
  • As detailed in a recently publishedresearchstudy ( Journal of Cannabis Research ) the KALY U.S. Patented CBD extract provides significant anti-inflammatory responsesin vitro.

KALY Evaluates Patented Cannabis Extract for Potential Coronavirus Treatment

Retrieved on: 
Monday, March 2, 2020
Medicine, Health, Herbalism, Medicinal plants, Appetite stimulants, Entheogens, Euphoriants, Chronic obstructive pulmonary disease, Cannabis, Respiratory disease, KALY, Medical cannabis

DALLAS, March 2, 2020 /PRNewswire/ --Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today again confirmed efforts to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms.KALY's proprietaryCBD formulation has been developed for the treatment of symptoms associated withChronic Obstructive Pulmonary Disease (COPD)and other similar respiratory conditions.

Key Points: 
  • DALLAS, March 2, 2020 /PRNewswire/ --Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today again confirmed efforts to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms.KALY's proprietaryCBD formulation has been developed for the treatment of symptoms associated withChronic Obstructive Pulmonary Disease (COPD)and other similar respiratory conditions.
  • The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company's U.S. Patented Cannabis Extraction Process.
  • As detailed in a recently publishedresearchstudy ( Journal of Cannabis Research ) the KALY U.S. Patented CBD extract provides significant anti-inflammatory responsesin vitro.
  • These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market.

Khiron is First Company Authorized to Extract High THC Medical Cannabis in Colombia

Retrieved on: 
Monday, March 2, 2020
Drugs, Entheogens, Euphoriants, Psychoactive drugs, Medicine, Medicinal plants, Appetite stimulants, Cannabinoids, Tetrahydrocannabinol, Cannabis, Medical cannabis, Cannabidiol

These quotas authorize the Company to manufacture high-THC whole plant extract for both export and domestic purposes.

Key Points: 
  • These quotas authorize the Company to manufacture high-THC whole plant extract for both export and domestic purposes.
  • Based on high-THC medical cannabis demand, the Company will be able to produce approximately an equivalent of 1,000,000 bottles of high-THC formulation for medical use domestically and abroad.
  • About Khiron Life Sciences Corp.
    Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.
  • Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.

Khiron Receives Approval of Normal Course Issuer Bid

Retrieved on: 
Friday, February 28, 2020
Drugs, Entheogens, Euphoriants, Psychoactive drugs, Medicinal plants, Medicine, Cannabinoids, Appetite stimulants, Cannabis, Tetrahydrocannabinol, Medical cannabis, Cannabidiol

About Khiron Life Sciences Corp.

Key Points: 
  • About Khiron Life Sciences Corp.
    Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.
  • Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
  • Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable).
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/khiron-receives-approval-of-norm...
    SOURCE Khiron Life Sciences Corp.

Nextleaf Solutions Prepares for Potential Pharmaceutical Participation with Prodrug Patent

Retrieved on: 
Thursday, February 27, 2020
Drugs, Cannabinoids, Organ systems, Chemical compounds, Entheogens, Euphoriants, Appetite stimulants, Antiemetics, THC-O-acetate, Tetrahydrocannabinol, Cannabidiol

The Company's latest U.S. patent is for the Acetylation of Cannabinoids, protecting the production of a cannabinoid-derived prodrug with unique medicinal properties and potential applications in the pharmaceutical industry.

Key Points: 
  • The Company's latest U.S. patent is for the Acetylation of Cannabinoids, protecting the production of a cannabinoid-derived prodrug with unique medicinal properties and potential applications in the pharmaceutical industry.
  • "Nextleaf's patented process produces THC-O-Acetate, a cannabinoid-derived metabolic prodrug with potentially very unique medicinal benefits associated with efficient and targeted drug delivery.
  • Nextleaf Solutions commercializes its patent portfolio through IP licensing, and supplying THC and CBD oils through Nextleaf Labs, a Health Canada licensed Standard Processor.
  • Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market inthe United States, andL0MAon the Frankfurt Stock Exchange.